Inhaled insulin Afrezza has launched in India, offering a needle-free option for diabetes management. Designed to overcome ...

A Prescription Drug User Fee Act target date of May 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...

This form of rapid-acting inhaled insulin, recently introduced in India by the name Afrezza, is said to offer an important ...

India’s Cipla Limited (BSE: 500087) announced the launch of Afrezza (insulin human) Inhalation Powder in India.

Poster 813; PS 068 Improved post-prandial blood glucose excursions with Technosphere inhaled insulin compared to aspart in adult patients with type 1 diabetes: STAT study intention to treat analysis ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled ...

ORLANDO, Fla. — The inhaled insulin Afrezza combined with a long-acting basal analog offers a non-inferior insulin treatment option for people with type 1 diabetes, new phase 4 data suggest. Afrezza ...

MannKind Corporation announced that it will present data from five studies on inhaled insulin at the 18th International Conference on Advanced Technologies and Treatments for Diabetes in Amsterdam, ...

Most of the 38 million people living with diabetes in the U.S. use daily injections or insulin pumps to keep glucose at safe levels — but new research suggests that a third option could be just as ...

MannKind Corporation (NASDAQ:MNKD) are trading lower Monday. The company released its six-month results from its Phase 3 INHALE-1 pediatric diabetes trial. Here’s what you need to know. What To Know: ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products ...